CellCentric widens drug screening in Shanghai
Cambridge, UK-based CellCentric, a biotechnology company unlocking epigenetic control mechanisms, has signed an enlarged agreement with HD Biosciences, a Shanghai, China-headquartered firm specializing in drug discovery contract research, in order to further build CellCentric's portfolio of drug discovery programs.
Prior to signing this expanded master services agreement, CellCentric and HDB worked together on an initial set of targets identified and prioritized by the UK group. The new deal provides a framework to drive these programs forward. HDB is acknowledged as a leading drug discovery contract research organization CRO, and the company was presented with Pfizer's 2008 Top Research Service Partner Award in recognition of the quality, productivity and value delivered to its client.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze